K Guidolin1, B Yaremko2,3, K Lynn4, S Gaede5, A Kornecki2,6, G Muscedere2,6, I BenNachum2,6, O Shmuilovich2,6, M Mouawad2, E Yu1,2, T Sexton1,2,3,4,5,6,7,8, N Gelman6, V Moiseenko7, M Brackstone2,8, M Lock1,2. 1. Department of Surgery, University of Toronto, Toronto, ON. 2. Division of Radiation Oncology, Department of Oncology, London Regional Cancer Program, London, ON. 3. Schulich School of Medicine and Dentistry, Western University, London, ON. 4. London Tumour Biobank, St. Joseph's Health Care, London, ON. 5. Medical Physics, London Regional Cancer Program, London, ON. 6. Department of Medical Imaging, St. Joseph's Health Care, London, ON. 7. Department of Radiation Medicine and Applied Sciences, School of Medicine, University of California-San Diego, San Diego, U.S.A. 8. Division of Surgical Oncology, Department of Surgery, London Health Sciences Centre, London, ON.
Abstract
Background and Purpose: Adjuvant whole-breast irradiation after breast-conserving surgery, typically delivered over several weeks, is the traditional standard of care for low-risk breast cancer. More recently, hypofractionated, partial-breast irradiation has increasingly become established. Neoadjuvant single-fraction radiotherapy (rt) is an uncommon approach wherein the unresected lesion is irradiated preoperatively in a single fraction. We developed the signal (Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy) trial, a prospective single-arm trial to test our hypothesis that, for low-risk carcinoma of the breast, the preoperative single-fraction approach would be feasible and safe. Methods:Patients presenting with early-stage (T < 3 cm), estrogen-positive, clinically node-negative invasive carcinoma of the breast with tumours at least 2 cm away from skin and chest wall were enrolled. All patients received prone breast magnetic resonance imaging (mri) and prone computed tomography simulation. Treatable patients received a single 21 Gy fraction of external-beam rt (as volumetric-modulated arc therapy) to the primary lesion in the breast, followed by definitive surgery 1 week later. The primary endpoints at 3 weeks, 6 months, and 1 year were toxicity and cosmesis (that is, safety) and feasibility (defined as the proportion of mri-appropriate patients receiving rt). Results: Of 52 patients accrued, 27 were successfully treated. The initial dosimetric constraints resulted in a feasibility failure, because only 57% of eligible patients were successfully treated. Revised dosimetric constraints were developed, after which 100% of patients meeting mri criteria were treated according to protocol. At 3 weeks, 6 months, and 1 year after the operation, toxicity, patient- and physician-rated cosmesis, and quality of life were not significantly different from baseline. Conclusions: The signal trial presents a feasible method of implementing single-dose preoperative rt in early-stage breast cancer. This pilot study did not identify any significant toxicity and demonstrated excellent cosmetic and quality-of-life outcomes. Future randomized multi-arm studies are required to corroborate these findings.
RCT Entities:
Background and Purpose: Adjuvant whole-breast irradiation after breast-conserving surgery, typically delivered over several weeks, is the traditional standard of care for low-risk breast cancer. More recently, hypofractionated, partial-breast irradiation has increasingly become established. Neoadjuvant single-fraction radiotherapy (rt) is an uncommon approach wherein the unresected lesion is irradiated preoperatively in a single fraction. We developed the signal (Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy) trial, a prospective single-arm trial to test our hypothesis that, for low-risk carcinoma of the breast, the preoperative single-fraction approach would be feasible and safe. Methods:Patients presenting with early-stage (T < 3 cm), estrogen-positive, clinically node-negative invasive carcinoma of the breast with tumours at least 2 cm away from skin and chest wall were enrolled. All patients received prone breast magnetic resonance imaging (mri) and prone computed tomography simulation. Treatable patients received a single 21 Gy fraction of external-beam rt (as volumetric-modulated arc therapy) to the primary lesion in the breast, followed by definitive surgery 1 week later. The primary endpoints at 3 weeks, 6 months, and 1 year were toxicity and cosmesis (that is, safety) and feasibility (defined as the proportion of mri-appropriate patients receiving rt). Results: Of 52 patients accrued, 27 were successfully treated. The initial dosimetric constraints resulted in a feasibility failure, because only 57% of eligible patients were successfully treated. Revised dosimetric constraints were developed, after which 100% of patients meeting mri criteria were treated according to protocol. At 3 weeks, 6 months, and 1 year after the operation, toxicity, patient- and physician-rated cosmesis, and quality of life were not significantly different from baseline. Conclusions: The signal trial presents a feasible method of implementing single-dose preoperative rt in early-stage breast cancer. This pilot study did not identify any significant toxicity and demonstrated excellent cosmetic and quality-of-life outcomes. Future randomized multi-arm studies are required to corroborate these findings.
Entities:
Keywords:
Radiation oncology; sbrt; stereotactic body radiotherapy
Authors: Janet K Horton; Rachel C Blitzblau; Sua Yoo; Joseph Geradts; Zheng Chang; Jay A Baker; Gregory S Georgiade; Wei Chen; Sharareh Siamakpour-Reihani; Chunhao Wang; Gloria Broadwater; Jeff Groth; Manisha Palta; Mark Dewhirst; William T Barry; Eileen A Duffy; Jen-Tsan A Chi; E Shelley Hwang Journal: Int J Radiat Oncol Biol Phys Date: 2015-03-14 Impact factor: 7.038
Authors: M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Jayant S Vaidya; Michael Baum; Jeffrey S Tobias; Frederik Wenz; Samuele Massarut; Mohammed Keshtgar; Basil Hilaris; Christobel Saunders; Norman R Williams; Chris Brew-Graves; Tammy Corica; Mario Roncadin; Uta Kraus-Tiefenbacher; Marc Sütterlin; Max Bulsara; David Joseph Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-15 Impact factor: 7.038
Authors: A P Forrest; H J Stewart; D Everington; R J Prescott; C S McArdle; A N Harnett; D C Smith; W D George Journal: Lancet Date: 1996-09-14 Impact factor: 79.321
Authors: Umberto Veronesi; Roberto Orecchia; Alberto Luini; Viviana Galimberti; Stefano Zurrida; Mattia Intra; Paolo Veronesi; Paolo Arnone; Maria Cristina Leonardi; Mario Ciocca; Roberta Lazzari; Pietro Caldarella; Nicole Rotmensz; Claudia Sangalli; Daniele Sances; Patrick Maisonneuve Journal: Breast Cancer Res Treat Date: 2010-08-15 Impact factor: 4.872
Authors: Bradford S Hoppe; Benjamin Laser; Alex V Kowalski; Sandra C Fontenla; Elizabeth Pena-Greenberg; Ellen D Yorke; D Michael Lovelock; Margie A Hunt; Kenneth E Rosenzweig Journal: Int J Radiat Oncol Biol Phys Date: 2008-12-01 Impact factor: 7.038
Authors: Joanne S Haviland; J Roger Owen; John A Dewar; Rajiv K Agrawal; Jane Barrett; Peter J Barrett-Lee; H Jane Dobbs; Penelope Hopwood; Pat A Lawton; Brian J Magee; Judith Mills; Sandra Simmons; Mark A Sydenham; Karen Venables; Judith M Bliss; John R Yarnold Journal: Lancet Oncol Date: 2013-09-19 Impact factor: 41.316
Authors: Maureen L Groot Koerkamp; H J G Desirée van den Bongard; Marielle E P Philippens; Femke van der Leij; Stefano Mandija; Antonetta C Houweling Journal: Phys Imaging Radiat Oncol Date: 2022-07-05
Authors: Maureen L Groot Koerkamp; Jeanine E Vasmel; Nicola S Russell; Simona F Shaitelman; Carmel N Anandadas; Adam Currey; Danny Vesprini; Brian M Keller; Chiara De-Colle; Kathy Han; Lior Z Braunstein; Faisal Mahmood; Ebbe L Lorenzen; Marielle E P Philippens; Helena M Verkooijen; Jan J W Lagendijk; Antonetta C Houweling; H J G Desiree van den Bongard; Anna M Kirby Journal: Front Oncol Date: 2020-07-28 Impact factor: 6.244